Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A clinical-stage medical device company focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The lead product, NB1, is currently in a pilot clinical study in Australia. The Company has no significant operating history and has incurred accumulated losses of approximately $87.4 million since inception.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenues | $0 | $0 | $0 | $0 |
| Net Loss | $(666,737) | $(941,002) | $(2,424,348) | $(2,590,705) |
| Operating Expenses | $715,274 | $951,021 | $2,501,837 | $2,664,223 |
| Research & Development | $187,808 | $429,747 | $802,994 | $1,025,814 |
| General & Administrative | $527,466 | $521,274 | $1,698,843 | $1,638,409 |
| Cash and Cash Equivalents (End of Period) | $6,049,084 (as of Sept 30, 2025) | |||
| Net Cash Used in Operating Activities (YTD) | $(1,976,388) | $(2,771,438) | ||
| Net Cash Provided by Financing Activities (YTD) | $4,700,341 | $3,311,295 | ||
| Warrant Liability | $1,201 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 24.8% in Q3 2025 compared to Q3 2024, primarily driven by a 56.3% reduction in Research and Development (R&D) costs due to the timing of clinical trial activities. YTD operating expenses decreased by 6.1%.
- Net Loss: Net loss improved (decreased) by 29.2% in Q3 2025 and 6.4% YTD 2025 compared to the prior year periods.
- Interest Income: Interest income increased significantly by 136.7% in Q3 2025 and 109.1% YTD 2025, reflecting higher yields on cash balances.
- Capital Structure: The Company executed a 1-for-6 reverse stock split effective June 10, 2025. All share and per-share data have been retroactively restated.
- Financing Activity: In June 2025, the Company completed a public offering raising net proceeds of approximately $4.35 million. Additionally, the Company raised $347,549 through its At-The-Market (ATM) facility during the nine months ended September 30, 2025.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. With cash of $6.0 million as of September 30, 2025, management estimates available funds will support operations into the fourth quarter of 2026. Operating expenditures for the next 12 months are estimated at $6.9 million.
- Future Financing: The Company intends to raise additional debt or equity financing. Failure to secure funding may require scaling back or discontinuing product development programs.
- Clinical Progress: The pilot clinical study for NB1 in Australia is ongoing. The Company anticipates continued substantial investment in development activities as it prepares for a pivotal clinical study in the future.
- Unusual Items:
- Warrant Liability: The Company recorded a gain of $3,469 YTD 2025 related to the change in fair value of warrant liability, compared to a gain of $38,122 in the prior year period.
- Stock-Based Compensation: Stock-based compensation expense increased to $210,684 YTD 2025 from $88,065 in the prior year period.
- Risks: Key risks include the ability to raise capital, regulatory approval (FDA PMA) for NELL-1/DBM, success of clinical trials, and reliance on third-party manufacturers.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $6.9 million operating expenditure estimate for the next 12 months against the current $6.0 million cash balance to assess the urgency of future capital raises.
- Clinical Trial Status: Confirm the current enrollment status and preliminary safety data of the NB1 pilot clinical study in Australia.
- Dilution Impact: Review the terms of the June 2025 public offering and the outstanding warrant liability (2.88 million warrants) to understand potential future dilution.
- Reverse Stock Split: Ensure all historical financial data is reviewed with the understanding that share counts and per-share metrics have been retroactively adjusted for the 1-for-6 reverse split.
- Going Concern Opinion: Review the independent auditor's report in the 2024 10-K regarding the substantial doubt on the Company's ability to continue as a going concern.